Replies to post #36914 on Relief Therapeutics Holding AG (RLFTF)

[J-Belfort]

“We are excited that ZYESAMI has demonstrated a highly significant reduction in time to hospital discharge for seriously ill COVID-19 patients treated with High Flow Nasal Oxygen, along with an increased likelihood of recovery and excellent safety,” said Jonathan C. Javitt, M.D., M.P.H., CEO of NeuroRx. “Although our current production methods yield a drug that is sufficiently stable for emergency use, a long-term, shelf-stable formulation will be needed for ongoing use of ZYESAMI, once the pandemic subsides. The thin-film freezing technology holds great promise in potentially making this available to patients with other stages of COVID-19 with an inhaled form of ZYESAMI."

https://www.businesswire.com/news/home/20210309005660/en/NeuroRX-and-TFF-Pharmaceuticals-Announce-Entering-Into-Feasibility-Collaboration


I do not think Dr Javitt would make that statement on a 03/09/21 press release if there was an issue with the 60 day data which he has seen.